RSV vaccination was effective in preventing RSV-related illness, including associated health-care use, in adults aged 60 years and older during the 2023–24 respiratory illness season, supporting current recommendations for vaccination in this populatio...
Winter viruses like influenza and respiratory syncytial virus (RSV) continue to be important causes of mortality in older adults. During the UN Decade of Healthy Ageing (2021–30), and nearly seven decades after the discovery of RSV, the first vaccine a...
In 2022, vaccine-derived polioviruses (VDPVs) emerged as a potential threat to global polio eradication.1 The first known outbreak of VDPV infection was reported in Hispaniola in 2000–012 and was associated with VDPV type 1. Since 2005, outbreaks due t...
The incidence of syphilis has increased steadily over the past 25 years. Undiagnosed cases have presumably increased in the same proportions, and rare complications are at particularly high risk of being unrecognised. A previously healthy 60-year-old m...
Antimicrobial resistance continues to be a growing threat globally, specifically in health-care settings in which antimicrobial-resistant pathogens cause a substantial proportion of health-care-associated infections (HAIs). Next-generation sequencing (...
Bennett JC, Deloria Knoll M, Kagucia EW, et al. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis 2024; publ...
Macià D, Campo JJ, Jairoce C, et al. The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a...
Macià D, Campo JJ, Jairoce C, et al. The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a...
SPAQ and dihydroartemisinin–piperaquine effectively reduced malaria in children younger than 5 years, with no safety concerns. There was no evidence of resistance selection by SMC. Although these findings support SPAQ-based SMC in Eastern and Southern ...
SPAQ and dihydroartemisinin–piperaquine effectively reduced malaria in children younger than 5 years, with no safety concerns. There was no evidence of resistance selection by SMC. Although these findings support SPAQ-based SMC in Eastern and Southern ...
Seasonal malaria chemoprevention (SMC) has emerged as a primary intervention in malaria control, protecting more than 49 million children in 2022, primarily in West Africa's Sahel region.1 WHO now recommends SMC in all areas where more than 60% of mala...
Seasonal malaria chemoprevention (SMC) has emerged as a primary intervention in malaria control, protecting more than 49 million children in 2022, primarily in West Africa's Sahel region.1 WHO now recommends SMC in all areas where more than 60% of mala...
The coprimary endpoints were met, and NVX-CoV2601 was well tolerated. These interim data support NVX-CoV2601 use per guidance for XBB.1.5-directed COVID-19 vaccines and demonstrate the adaptability of this vaccine platform for updated SARS-CoV-2 spike ...
The cross-neutralising effects of COVID-19 vaccines given as prime–boost regimens have garnered much interest as SARS-CoV-2 has evolved. Several studies have shown that immunisation with heterologous vaccines, wherein the booster is based on a differen...
It became clear after the last call for malaria elimination in 2007 that Plasmodium vivax malaria would be a substantial bottleneck because of many evolutive advantages of this parasite, such as the early development of peripheral gametocytes and the d...
Substantial reductions in prevalence as measured by PCR were predicted with primaquine and tafenoquine regimens if these could be implemented with high coverage and adherence. The benefits of preventing P vivax relapses need to be balanced against the ...